NCT04108234已完成1 期
Safety, Tolerance and Pharmacokinetics of Hydrochloric Acid (R) -Ketamine Nasal Spray in Healthy Subjects: A Randomized, Double Blind, Placebo-Controlled Phase I Clinical Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Incidence of Adverse Events (Safety and Tolerability)
研究概览
简要总结
The study is being conducted to evaluate the safety and pharmacokinetics of HR071603 in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Obtain informed consent prior to the start of any activity related to the trial, and have a thorough understanding of the purpose and meaning of the trial and be willing to comply with the protocol;
- •Healthy males aged between 18 and 45 (including both ends);
- •Weight ≥ 50kg, body mass index (BMI) in the range of 18.5 ~ 23.9 (including both ends);
- •During the trial and within 30 days after the administration, willing to take contraceptive measures and ensure that no sperm is donated.
排除标准
- •A subject considered by the investigator to be unsuitable for nasal spray administration;
- •Allergic to any component of the study drug;
- •The underlying disease is not suitable for participation in the trial;
- •12-lead ECG results in the screening period are abnormal and clinically significant
- •Liver dysfunction;
- •Serum creatinine > 1.2 × ULN during screening period;
- •Screening for infectious diseases screening hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody, human immunodeficiency virus (HIV) antibody test positive;
- •Subject has been thoroughly examined, and the results are abnormal and clinically significant;
- •Major operations were performed within 3 months before the screening period.
- •Donate whole blood/plasma within one month before the screening period, or donate whole blood/plasma more than 400 ml within three months before the screening period;
- •Positive urine drug test;
- •The alcohol breath test is positive; or the average daily intake of alcohol exceeds 15g;
- •Nicotine test is positive;
- •History of drug abuse or alcohol abuse;
- •In the past three months, over five cups of coffee or tea per day were consumed in an average;
- •Any prescription drugs, over-the-counter drugs and health products were used within 2 weeks before screening.
- •Participated in clinical trials of any drug or medical device within 3 months before screening ;
- •Any other medical or psychological condition, which in the opinion of the Investigator, might create undue risk to the participant or interfere with the participant's ability to comply with the protocol requirements, or to complete the study.
研究组 & 干预措施
Treatment group A
Experimental
HR071603,nasal spray,dose escalation.
干预措施: HR071603 (Drug)
Treatment group B
Placebo Comparator
Placebo, nasal spray
干预措施: placebo (Drug)
结局指标
主要结局
Incidence of Adverse Events (Safety and Tolerability)
时间窗: Pre-dose to Day8
次要结局
- Assessment of PK parameter-Area under drug-time curve (AUC)(Pre-dose to Day2)
- Assessment of PK parameter-peak time (Tmax)(Pre-dose to Day2)
- Assessment of PK parameter-apparent clearance rate (CL/F)(Pre-dose to Day2)
- Assessment of PK parameter-apparent distribution volume (Vz/F)(Pre-dose to Day2)
- Assessment of PK parameter-peak concentration (Cmax)(Pre-dose to Day2)
- Assessment of PK parameter-half-life (t1/2)(Pre-dose to Day2)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Pharmacokinetic of Donepezil Pamoate in Healthy SubjectsADNCT03932916Shanghai Synergy Pharmaceutical Sciences Co., Ltd.38
Unknown
1 期
Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal InsufficientRenal Insufficiency,Type 2 DiabetesNCT03159832Jiangsu HengRui Medicine Co., Ltd.24
已完成
1 期
Study of XH-S003 in Healthy VolunteersHealthy AdultsNCT06272747S-INFINITY Pharmaceuticals Co., Ltd36
已完成
1 期
Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's DiseaseParkinson Disease, IdiopathicNCT06659562Herantis Pharma Plc.32
Unknown
1 期
A Study of SHR0410 in Hemodialysis Patients With PruritusPruritusNCT04317209Jiangsu HengRui Medicine Co., Ltd.54